2018
Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction
Milks M, Velez M, Mehta N, Ishola A, Van Houten T, Yildiz V, Reinbolt R, Lustberg M, Smith S, Orsinelli D. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. The American Journal Of Cardiology 2018, 121: 867-873. PMID: 29454478, DOI: 10.1016/j.amjcard.2017.12.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalAtrial FibrillationAtrial FlutterBreast NeoplasmsCoronary Artery DiseaseDiabetes MellitusDoxorubicinEchocardiographyFemaleHeart FailureHumansHypertensionLogistic ModelsMiddle AgedRenal InsufficiencyReproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsStroke VolumeTrastuzumabVentricular DysfunctionConceptsCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainRisk factorsEchocardiographic variablesCardiac dysfunctionLongitudinal strainImaging assessmentCertain clinical risk factorsHeart failure risk factorsVentricular global longitudinal strainLeft ventricular longitudinal strainClinical risk factorsLV ejection fractionVentricular longitudinal strainHigh-risk groupRisk prediction toolsFailure risk factorsReceiver-operating characteristicClinical factorsEjection fractionOncologic treatmentLV functionRetrospective studyClinical variablesBreast cancer
2012
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.Peer-Reviewed Original ResearchConceptsPotential imaging markerPathologic responseBreast cancerTumor heterogeneityImaging markerHER-2 negative breast cancerImaging biomarkersVolumetric biomarkersCombination neoadjuvant chemotherapyCurrent imaging studiesGood predictive biomarkerNegative breast cancerTherapeutic response assessmentNovel imaging biomarkersNeoadjuvant chemotherapyRetrospective studyPredictive biomarkersNovel biomarkersResponse assessmentHeterogeneous diseaseEarly changesImaging studiesBiomarkersCancerCellular composition